Comparison Overview

Alispharm by CBTW

VS

Hetero Drugs Ltd

Alispharm by CBTW

2, Quai du Commerce, Lyon, Auvergne-Rhône-Alpes, 69009, FR
Last Update: 2025-03-16 (UTC)
Between 750 and 799

Alispharm is an integral part of Collaboration Betters The World (CBTW), a global tech solutions company that believes in the transformative power of collaboration. CBTW’s approach combines deep industry insights with a broad range of services designed to deliver results for our clients. Its areas of expertise include Strategy & Consulting, Innovation & Design, Technology & Engineering, and Industry-Specific offerings. Operating in over 20 countries with a team of 4,000 tech experts, CBTW offers solutions that not only tackle technological and operational challenges but also aim to create a positive impact. In line with its mission, CBTW dedicate time, resources, and expertise to education projects, creating a lasting impact on our teams, communities, and planet. We, at ALispharm, support Pharmaceutical, Biotechnology and Medical Devices Manufacturers in the development of their healthcare products. We intervene at every stage of the lifecycle of a health product and accompanies its customers on a wide range of challenges and projects. We have 4 core domains of expertise : Quality Assurance, Qualification / Validation, Regulatory Affairs, Quality Control and Industrialization.

NAICS: 325
NAICS Definition:
Employees: 189
Subsidiaries: 24
12-month incidents
0
Known data breaches
0
Attack type number
0

Hetero Drugs Ltd

India Hyderabad, 500018, IN
Last Update: 2025-05-06 (UTC)
Between 750 and 799

Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & Finished Dosages. Ever since its establishment in 1993, Hetero showed a tradition of excellence and deep sense of commitment in developing cost effective processes to offer wide range of affordable drugs.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 10,001+
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/alispharm.jpeg
Alispharm by CBTW
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/hetero-drugs-ltd.jpeg
Hetero Drugs Ltd
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Alispharm by CBTW
100%
Compliance Rate
0/4 Standards Verified
Hetero Drugs Ltd
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Alispharm by CBTW in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Hetero Drugs Ltd in 2025.

Incident History — Alispharm by CBTW (X = Date, Y = Severity)

Alispharm by CBTW cyber incidents detection timeline including parent company and subsidiaries

Incident History — Hetero Drugs Ltd (X = Date, Y = Severity)

Hetero Drugs Ltd cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/alispharm.jpeg
Alispharm by CBTW
Incidents

No Incident

https://images.rankiteo.com/companyimages/hetero-drugs-ltd.jpeg
Hetero Drugs Ltd
Incidents

No Incident

FAQ

Hetero Drugs Ltd company demonstrates a stronger AI Cybersecurity Score compared to Alispharm by CBTW company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, Hetero Drugs Ltd company has disclosed a higher number of cyber incidents compared to Alispharm by CBTW company.

In the current year, Hetero Drugs Ltd company and Alispharm by CBTW company have not reported any cyber incidents.

Neither Hetero Drugs Ltd company nor Alispharm by CBTW company has reported experiencing a ransomware attack publicly.

Neither Hetero Drugs Ltd company nor Alispharm by CBTW company has reported experiencing a data breach publicly.

Neither Hetero Drugs Ltd company nor Alispharm by CBTW company has reported experiencing targeted cyberattacks publicly.

Neither Alispharm by CBTW company nor Hetero Drugs Ltd company has reported experiencing or disclosing vulnerabilities publicly.

Neither Alispharm by CBTW nor Hetero Drugs Ltd holds any compliance certifications.

Neither company holds any compliance certifications.

Alispharm by CBTW company has more subsidiaries worldwide compared to Hetero Drugs Ltd company.

Alispharm by CBTW company employs more people globally than Hetero Drugs Ltd company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Alispharm by CBTW nor Hetero Drugs Ltd holds SOC 2 Type 1 certification.

Neither Alispharm by CBTW nor Hetero Drugs Ltd holds SOC 2 Type 2 certification.

Neither Alispharm by CBTW nor Hetero Drugs Ltd holds ISO 27001 certification.

Neither Alispharm by CBTW nor Hetero Drugs Ltd holds PCI DSS certification.

Neither Alispharm by CBTW nor Hetero Drugs Ltd holds HIPAA certification.

Neither Alispharm by CBTW nor Hetero Drugs Ltd holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

The Bold Page Builder plugin for WordPress is vulnerable to Stored Cross-Site Scripting via the ‘percentage’ parameter in all versions up to, and including, 5.4.5 due to insufficient input sanitization and output escaping. This makes it possible for authenticated attackers, with Contributor-level access and above, to inject arbitrary web scripts in pages that will execute whenever a user accesses an injected page.

Risk Information
cvss3
Base: 6.4
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:L/I:L/A:N
Description

The ComboServlet in Liferay Portal 7.4.0 through 7.4.3.111, and older unsupported versions, and Liferay DXP 2023.Q4.0 through 2023.Q4.2, 2023.Q3.1 through 2023.Q3.5, 7.4 GA through update 92, 7.3 GA through update 35, and older unsupported versions does not limit the number or size of the files it will combine, which allows remote attackers to create very large responses that lead to a denial of service attack via the URL query string.

Risk Information
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary directories on the target machine.

Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and create arbitrary directories on the target machine.

Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary files on the target machine.

Risk Information
cvss3
Base: 7.5
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:H
cvss4
Base: 8.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:H/SC:N/SI:L/SA:L/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X